Moderna (MRNA) Cash from Investing Activities (2018 - 2026)

Moderna (MRNA) has reported Cash from Investing Activities for 9 consecutive years, with $329.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 41.67% year-over-year to $329.0 million in Q2 2026; TTM through Jun 2026 was $905.0 million, a 38.69% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, changed 0.15% from the prior year.
• Cash from Investing Activities was $329.0 million for Q2 2026 at Moderna, up from -$76.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $2.0 billion in Q1 2023 and troughed at -$3.9 billion in Q1 2022.
• A 5-year average of $176.6 million and a median of $446.5 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 2078.33% in 2022 and jumped 518.64% in 2025, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$1.0 billion in 2022, then jumped by 48.66% to -$538.0 million in 2023, then slipped by 0.19% to -$539.0 million in 2024, then surged by 91.09% to -$48.0 million in 2025, then surged by 785.42% to $329.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $329.0 million (Q2 2026), -$76.0 million (Q1 2026), and -$48.0 million (Q4 2025), per Business Quant data.